Search the Community
Showing results for tags 'Dopamine'.
Found 2 results
I, and a number of other CR practitioners I know, eat what most people would consider a very monotonous diet - eating (virtually) the same thing nearly every day. And usually not what most people would consider the tastiest of foods either, since most people's palates find the tastiest foods to be those that are generally not very health (e.g. cakes, pies, cookies, pizza, chips, etc.), and thus we tend to limit them or avoid them altogether. As a result, my wife and family have often wondered how I can stand to eat the same thing every day, and I've wondered it too. Why do I look forward to eating, and specifically the taste of, my same-old (one) meal every day? This new study  (press release) posted by Al Pater to the CR email list (thanks Al!) may provide a clue. Some caution is on order in extrapolating to humans the results of , since it was conducted in isolated slices of neurons from the brains of rats. But it is interesting nonetheless for what it suggests about the reward value of food, particularly for animals (and maybe people) subjected to calorie restriction. So here goes... In the main part of the study, they had three groups of rats, labelled FR (food restricted), AL (ad lib) and OB (obese rats, fed three different diets: AL rats had free access to standard rat chow. [FR] rats received 40–50% of AL intake of standard rat chow daily until body weight was reduced by 20%, after which food was titrated to maintain this weight. OB rats had free access to rat chow and chocolate Ensure, a highly palatable liquid with moderately high fat and sugar Not surprisingly, by the end of the four week diet intervention, the OB rats were fat, and the FR rats were thin and had a much lower level of circulating serum insulin than either AL or OB rats. They then isolated slices from parts of the striatum of the brains of the rats in the three groups. The striatum is known to be part of the mammalian reward system, and is the primary brain area associated with the neurotransmitter dopamine, the release of which is known to be associated with all types of reward, including food reward, not to mention the reward from drugs like cocaine. Slices from the FR rats were exposed to insulin, since insulin level in the brain have been previously shown to influence dopamine release. But the previous results were ambiguous - insulin has previously appeared to increase both dopamine release and dopamine reuptake, so it hasn't been clear whether increased insulin in the brain (e.g. after eating a meal with glucose) would result in a net increase or decrease in dopamine signalling, particularly in the reward center (striatum). What these researchers found was quite unambiguous. In slices from the FR rats' striatum, dopamine release was extremely sensitive to insulin level - in fact 10x more sensitive than the AL rats. In other words, it took very little insulin for the FR rats' striatum to release lots of dopamine. In contrast, the obese (OB) rats showed just the opposite. Their tendency to release dopamine was a lot less sensitive to insulin than AL, and especially FR rats brain slices. Here is the relevant graph from the full text of the paper: It shows the amount of dopamine released (y-axis) in response to various levels of infused insulin (x-axis) in three different parts of the striatum, for the FR (blue) and OB (maroon) rats. What you can see is that in all three areas, it took nearly two orders of magnitude more insulin to trigger the same amount of dopamine release in the OB rats as the FR rats (e.g. 10-30 nM for OB vs 0.3 nM for FR). Put another way - at low levels of insulin (e.g. 0.3 or 1.0 nM), the FR rats brains were releasing a substantial amount of dopamine, significantly more than AL controls, while the OB rats weren't releasing any dopamine (i.e. 0% of AL controls). In short, CR rats (and maybe humans) appear to get a lot more "bang for their buck" from food - i.e. a greater feeling of reward (via increased dopamine) from a given amount of food/glucose/insulin ingested. So perhaps this could explain in part why CR practitioners find their modest diets (modest both in terms of calories and palatability) to continue to be rewarding - we're getting a big dopamine release relatively to 'normal' people because of the increased sensitivity of our brain's reward center to insulin. Regarding palatability, the researchers in  went a step further, using a different set of rats (obviously, since the first set was dead ). In this second part of the experiment, they investigated the effect of blocking insulin action in the reward center of behaving rats on the development of food preferences. Specifically, they gave rats two glucose sweetened beverages, with different flavorings added to make them distinguishable, but both still quite palatable. They gave rats each of the two drinks, but alternating them from one day to the next. Whenever the rats received one of them, they paired it with an injection of an insulin-blocking agent to their striatum, to prevent the insulin spike following consumption of the drink from triggering a rewarding dopamine release. With the other beverage, they didn't block insulin, and therefore didn't block the rewarding release of dopamine that resulted from consuming the second beverage. As you might predict by now, when the rats were given free access to the two beverages after this conditioning, the rats preferred the beverage where insulin hadn't been blocked, presumably because they'd developed a taste preference for that flavor as a result of its consistent pairing with dopamine release in the striatum. Extrapolating to human CR practitioners - this might explain why we find our simple, monotonous diet so palatable. Specifically, our brains release a lot of dopamine in response to the insulin spike when we eat, so the taste of our monotonous diet becomes associated with the "good feeling" produced by dopamine, in a way not so different from the positive sensation produced by cocaine, which blocks dopamine reuptake at synapses in the striatum, thereby effectively increasing dopamine signalling. In summary, this study appears to suggest (assuming these rat results can be extrapolated to humans) that one's palate (i.e. food preferences) really does change, as many people have reported, as a result of eating a calorie-restricted, healthy, but not-especially-tasty diet for an extended period of time, and that this change is mediated by insulin signaling, insulin sensitivity, and dopamine release in the brain's reward center. --Dean ------------  Nat Commun. 2015 Oct 27;6:8543. doi: 10.1038/ncomms9543. Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. Stouffer MA(1,)(2), Woods CA(3), Patel JC(2), Lee CR(2), Witkovsky P(4), Bao L(1,)(2), Machold RP(5), Jones KT(6), de Vaca SC(6), Reith ME(6,)(7), Carr KD(6,)(7), Rice ME(1,)(2). Free full text: http://www.nature.com/ncomms/2015/151027/ncomms9543/full/ncomms9543.html Press release: http://www.eurekalert.org/pub_releases/2015-10/nlmc-nrf102215.php Insulin activates insulin receptors (InsRs) in the hypothalamus to signal satiety after a meal. However, the rising incidence of obesity, which results in chronically elevated insulin levels, implies that insulin may also act in brain centres that regulate motivation and reward. We report here that insulin can amplify action potential-dependent dopamine (DA) release in the nucleus accumbens (NAc) and caudate-putamen through an indirect mechanism that involves striatal cholinergic interneurons that express InsRs. Furthermore, two different chronic diet manipulations in rats, food restriction (FR) and an obesogenic (OB) diet, oppositely alter the sensitivity of striatal DA release to insulin, with enhanced responsiveness in FR, but loss of responsiveness in OB. Behavioural studies show that intact insulin levels in the NAc shell are necessary for acquisition of preference for the flavour of a paired glucose solution. Together, these data imply that striatal insulin signalling enhances DA release to influence food choices. PMCID: PMC4624275 PMID: 26503322
Dean Pomerleau posted a topic in CR Science & TheoryEver since CR pioneer Roy Walford died of amyotrophic lateral sclerosis (ALS - or something resembling ALS), there has been some concern that CR may not protect against, and may in fact hasten, neurodegenerative diseases, particularly those involving dopaminergic neurons, like ALS, Parkinson's Disease (PD) and Multiple Sclerosis (MS). This new study  by Ingram et al posted by James in his latest weekly CR research update (thanks James!), suggests otherwise. It found that adult-onset CR in rats was protective against bradykinesia, a slowness of movement which is a hallmark of Parkinson's disease. They also found elevated levels of dopamine in an important brain region implicated in PD, the substantia nigra. This result supports an earlier, perhaps more germane finding from a study of primates done by Ingram's group in 2004 . In , Ingram et al found that 30% CR for six months in adult male rhesus monkeys protected against a drop in dopamine level and dopamine neuron cell death when the (unfortunate ) monkeys were exposed to a neurotoxin that mimics Parkinson's Disease in primates. So overall that is more encouraging news for CR & brain health - on top of the finding of preserved white matter by CR I reported on earlier. In researching this post, I came across a review article  about a possible link between these three neurodegenerative diseases (PD, ALS & MS) and iodine. It observed that in regional population studies, long-term dietary iodine deficiency is associated with all three of these diseases, and may be explained by iodine deficiency interfering with dopamine and dopaminergic neurons. Whether this link holds up under scrutiny I'm not sure, but it is another possible reason to make sure one isn't deficient in iodine. Unfortunately, iodine is not well represented in the USDA (or any other) food database. For many people who consumed a low sodium diet, and in particular don't consume iodized salt, iodine deficiency is a real concern. That's why I supplement with the RDA (150mcg) of iodine per day. Note - high sodium processed foods typically do not contain iodine, so even the general population may be iodine deficient if they aren't eating foods with iodized salt. --Dean ----------  Neurobiol Aging. 2015 Oct 19. pii: S0197-4580(15)00495-9. doi: 10.1016/j.neurobiolaging.2015.10.006. [Epub ahead of print] Initiation of calorie restriction in middle-aged male rats attenuates aging-related motoric decline and bradykinesia without increased striatal dopamine. Salvatore MF(1), Terrebonne J(2), Fields V(3), Nodurft D(3), Runfalo C(2), Latimer B(3), Ingram DK(2). Aging-related bradykinesia affects ∼15% of those reaching age 65 and 50% of those reaching their 80s. Given this high risk and lack of pharmacologic therapeutics, noninvasive lifestyle strategies should be identified to diminish its risk and identify the neurobiological targets to reduce aging-related bradykinesia. Early-life, long-term calorie restriction (CR) attenuates aging-related bradykinesia in rodents. Here, we addressed whether CR initiation at middle age could attenuate aging-related bradykinesia and motoric decline measured as rotarod performance. A 30% CR regimen was implemented for 6 months duration in 12-month-old male Brown-Norway Fischer 344 F1 hybrid rats after establishing individual baseline locomotor activities. Locomotor capacity was assessed every 6 weeks thereafter. The ad libitum group exhibited predictably decreased locomotor activity, except movement speed, out to 18 months of age. In contrast, in the CR group, movement number and horizontal activity did not decrease during the 6-month trial, and aging-related decline in rotarod performance was attenuated. The response to CR was influenced by baseline locomotor activity. The lower the locomotor activity level at baseline, the greater the response to CR. Rats in the lower 50th percentile surpassed their baseline level of activity, whereas rats in the top 50th percentile decreased at 6 weeks and then returned to baseline by 12 weeks of CR. We hypothesized that nigrostriatal dopamine tissue content would be greater in the CR group and observed a modest increase only in substantia nigra with no group differences in striatum, nucleus accumbens, or ventral tegmental area. These results indicate that initiation of CR at middle age may reduce aging-related bradykinesia, and, furthermore, subjects with below average locomotor activity may increase baseline activity. Sustaining nigral dopamine neurotransmission may be one component of preserving locomotor capabilities during aging. Copyright © 2015 Elsevier Inc. All rights reserved. PMID: 26610387 -----------  Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18171-6. Epub 2004 Dec 16. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Maswood N(1), Young J, Tilmont E, Zhang Z, Gash DM, Gerhardt GA, Grondin R, Roth GS, Mattison J, Lane MA, Carson RE, Cohen RM, Mouton PR, Quigley C, Mattson MP, Ingram DK. Author information: (1)Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA. Comment in Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):17887-8. We report that a low-calorie diet can lessen the severity of neurochemical deficits and motor dysfunction in a primate model of Parkinson's disease. Adult male rhesus monkeys were maintained for 6 months on a reduced-calorie diet [30% caloric restriction (CR)] or an ad libitum control diet after which they were subjected to treatment with a neurotoxin to produce a hemiparkinson condition. After neurotoxin treatment, CR monkeys exhibited significantly higher levels of locomotor activity compared with control monkeys as well as higher levels of dopamine (DA) and DA metabolites in the striatal region. Increased survival of DA neurons in the substantia nigra and improved manual dexterity were noted but did not reach statistical significance. Levels of glial cell line-derived neurotrophic factor, which is known to promote the survival of DA neurons, were increased significantly in the caudate nucleus of CR monkeys, suggesting a role for glial cell line-derived neurotrophic factor in the anti-Parkinson's disease effect of the low-calorie diet. PMCID: PMC539733 PMID: 15604149 ---------------  Journal of Orthomolecular Medicine Vol. 14, 3rd Quarter 1999 Parkinson’s Disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis: The Iodine-Dopachrome-Glutamate Hypothesis Harold D. Foster Full text: http://orthomolecular.org/library/jom/1999/articles/1999-v14n03-p128.shtml Abstract Background. Globally, Parkinsonism, multiple sclerosis and amyotrophic lateral sclerosis mortalities tends to increase with latitude. These disorders also display a north-south gradient in the coterminous United States. This spatial distribution suggests their etiologies are significantly influenced by one or more geographical variables. Methods. Pearson’s correlation was used to compare mortalities, at the state scale, in the United States, from these three neurologic disorders and the spatial patterns of 81 other diseases and 219 environmental variables. Results. The resulting correlations suggest that mortality from Parkinsonism, multiple sclerosis and amyotrophic lateral sclerosis occurs most often in recently glaciated, iodine deficient regions, that were formerly marked by elevated goiter prevalence. Conclusions. Long-term iodine deficiency appears linked to abnormalities in the dopaminergic system that include an increased number of dopamine receptors. It is argued that this raises susceptibility to dopamine oxidation which, in turn, causes deficiencies of the antioxidant enzymes Cu/Zn superoxide dismutase, glutathione peroxidase and catalase. Dopamine deficiency also leads to elevated cytotoxic glutamate levels. Implications of the iodine-dopachrome-glutamate hypothesis, for treatment of these three neurologic disorders, are then discussed. Possible interventions include the use of levodopa, vitamin B3, Coenzyme Q10, various antioxidants, amino acids, iodine and glutamate antagonists. Key words: Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis, glaciation, iodine, goiter, dopamine, dopachrome, glutamate, oxidative stress.